UM LAPs - UG1 Grant

UM LAP - UG1 补助金

• 批准号: 9892985
• 负责人: MARK M ZALUPSKI
• 金额: $ 63.37万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-13 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9892985
• 关键词: Adjuvant Therapy; Adoption; Adult; Award; Awareness; Basic Science; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Collection; Comprehensive Cancer Center; Data; Development; Discipline; Enrollment; Ethics; Faculty; Goals; Grant; Healthcare Systems; Institution; Laws; Lead; Leadership; Mentors; Michigan; Modality; National Clinical Trials Network; Patient-Focused Outcomes; Patients; Play; Policies; Postdoctoral Fellow; Process; Prognostic Factor; Protocol Compliance; Protocols documentation; Reporting; Research; Resources; Role; Site; Talents; Toxic effect; Training; Translating; Universities; Veterans; anticancer research; cancer care; cancer therapy; data management; improved; medical schools; rare cancer; response; therapy outcome

PROJECT SUMMARY The University of Michigan (UM), inclusive of its Comprehensive Cancer Center (UMCCC) and Medical School Departments, requests this UG1 award as an NCI National Clinical Trials Network Lead Academic Participating Site (NCTN LAPS-UG1). We view this opportunity as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goal as a LAPS site is to make significant scientific, leadership, administrative and patient data contributions to the NCTN effort to study and improve cancer therapy. The NCTN process involves the development and conduct of purposeful clinical trials, adoption of uniform toxicity and response criteria, collection of patient data, and results reporting. NCTN Group research is the only setting in which sophisticated concepts of combined modality and interdisciplinary therapy as well as adjuvant therapies can be properly evaluated. NCTN clinical research has also provided an improved understanding of the important relationships between prognostic factors, therapy and patient outcomes that could not have been obtained otherwise.

项目摘要 密歇根大学（UM），包括其综合癌症中心（UMCCC）和 医学院部门，要求该UG1奖作为NCI国家临床试验 网络负责学术参与站点（NCTN LAPS-ug1）。我们将这个机会视为 我们机构进行大型癌症研究工作的重要组成部分。我们仍然承诺 关于多机构合作对于癌症发展至关重要的概念 治疗。我们作为圈圈站点的目标是建立重要的科学，领导，行政 以及患者的数据贡献，以研究和改善癌症治疗的努力。这 NCTN过程涉及有目的的临床试验的开发和行为，采用 均匀的毒性和反应标准，患者数据的收集以及结果报告。 NCTN 小组研究是唯一复杂的合并方式概念和 可以正确评估跨学科疗法以及辅助治疗。 NCTN临床 研究还提高了人们对之间重要关系的理解 否则无法获得的预后因素，治疗和患者结局。